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Innovations
Hydra Biosciences
Inducing Nature’s Regenerative Power
bott Laboratories. Series B funding study the process of regeneration.
But, as Dr. Li points out, “treating ze-was complete in December 2003.
brafish isn’t high on my list of thingsWhile at Utah, Li and Keating were
Although Hydra Biosciences is in the
business of finding new ways to re-
pair and regenerate injured heart cell
tissues, they are not a cell-based to pursue within a company, but un-involved in vascular regeneration
therapy company. This means no derstanding and harnessing mamma-and cardiac regeneration, respec-
stem cells. Instead, this 20-person lian regeneration is.” So the companytively. Hence, the regeneration-
Cambridge, MA-based company is is turning exclusively to mammalianbased company was established in
hot in pursuit of proteins and small models. Others have already provided2001. Many of the first employees at
molecules to do the job instead. The evidence that human cardiac myo-Hydra have since migrated from the
idea is to change the balance of nor- cytes, once injured, can regenerate toClapham/Keating lab at Harvard.
mal biologic function to enhance some point. (For further details, see
proliferation of the cardiac myocytes Beltrami, A.P. et al., N. Engl. J. Med.
where it is needed—and impede it 344, pp. 1750–1757, “Evidence that“Much of the interest inwhere it could be harmful. human cardiac myocytes divide after
the company is due to the“Much of the interest in the com- myocardial infarction.”) “For mamma-
lian cardiac regeneration to work, youpany is due to the fact that lots of fact that lots of people are
people are interested in the promise may have to give extra of some fac-
interested in the promiseof regeneration medicine and the tors that are highly expressed in fetal
cardiac myocytes that aren’t so muchcontroversy associated with the eth- of regeneration medicine
ics of stem cell biology,” says Dr. in adult heart cells,” says Dr. Li. Thisand the controversy as-
Dean Y. Li, MD, PhD, Scientific Co- is how he screens for factors at Hydra
sociated with the ethicsfounder of Hydra and Associate Pro- Biosciences. “But you may also have
to block a competing process, suchfessor of Medicine, University of of stem cell biology.”
Utah. “The drive behind embryonic as cardiac fibrosis or scarring,” he–Dean Y. Li, PhD, Scien-
stem cells is to guide them into form- says. “For a maximal response, we’ll
tific Cofounder, Hydraing heart cells, for example, and de- have to find nuance to balance both.”
livering them to a patient.” But he Hydra is now trying to prove if they
believes delivering cells, which also can get a factor to induce mammalian
“Hydra has three major projects,includes whole organ heart trans- cardiomyocytes to grow in an animal
the primary being the regenerationplants, in his view, is difficult to model. Just as bone heals after an
project,” explains Matthew Gantz, Hy-achieve in practice. Instead, Hydra injury, Hydra believes there is a regen-
dra’s President and CEO. Much of thefocuses on developing and deliv- eration process that normally tries to
foundational work on this project wasering a medicine, not cells, to induce occur in the heart after trauma. “But
performed through Mark Keating’sthe body’s own heart cells to regen- it may not have advanced to the same
academic research on cardiac myo-erate. The approach would be less extent with cardiomyocytes, so the
cyte regeneration in zebrafish. Heintimidating ethically and, they process is not fast enough,” says
proved that zebrafish heart musclehope, easier for physicians to put Glenn R. Larsen, PhD, Chief Scientific
could regenerate, and he identified ainto practice. “Delivering a small Officer at Hydra.
way to dedifferentiate skeletal myo-molecule or biologic is much easier Though Hydra is not disclosing the
cytes. “The whole rush was to actuallyand can affect more lives,” says specific mechanisms, growth factors,
prove you could cause cardiac myo-Dr. Li. or small molecules it has discovered,
cytes to grow,” says Dr. Li. KeatingAcademic, Now Business, they have developed a body of evi-
published this work in Science (298,Partners dence showing rodent cardiac myo-
pp. 2188–2190, “Heart regeneration inAs with many start-up biotech com- cytes grow in culture systems. So
zebrafish”). Specifically, Keating andpanies, most of Hydra’s four found- while zebrafish need the cell-cycle
colleagues proved that zebrafish fullyers first became associated through regulator Mps1—what Keating et al.
regenerate hearts within 2 months oftheir work in academic labs: Dean Li describe as a “mitotic checkpoint ki-
20% ventricular resection. “But weand Mark Keating, PhD at Utah, and nase upregulated in many prolifera-
have moved beyond that to a pointDavid Clapham, PhD at Harvard (who tive cell types”—to repair their injured
where have developed a mammalian-recruited Keating to Harvard in 2001). hearts, not unexpectedly, the Hydra
based assay that enables us to screenLaurie Keating joined the team to pro- team has discovered that mammalian
primary adult and neonatal cardio-vide business development structure systems require different factors.
myocytes,” explains Mr. Gantz.and to initiate venture financing— “The factors we’ve identified are ca-
The zebrafish and newt are goodsuccessfully achieved through VC pable of promoting cardiac myocyte
growth from cells that have been iso-funding and a collaboration with Ab- organisms for an academic lab to
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586
lated from mammalian hearts,” says lect ion channels to develop drugs
for cardiovascular and inflammatoryDr. Larsen. The company developed
what they call “high-content assays” diseases. Explains Dr. Larsen, “Da-
vid Clapham is world class in ionof mature, differentiated mammalian
cardiomyocytes to test the effective- channel physiology.” Clapham’s most
recent publication on ion channelsness of these growth factors and
small molecules. “We anticipate these was published in Nature (426, pp.
517–524, “TRP channels as cellularfactors to correlate with their potential
to regenerate in whole animals,” says sensors”). “This is a highly drug-
gable target class both in terms ofDr. Larsen. “We are in a position now
where we are no longer concerned if identifying small molecule agonists
and antagonists to ion flux in cells,”we can find factors that induce car-
diac myocytes to grow in culture but says Larsen. As with the vascular
regeneration project, Hydra is seek-whether those factors are effective
in vivo.” ing partnerships for this program.
Vascular Wall Regeneration
Chemistry & Biology invites yourFurther on in development is a project
comments on this topic. Pleaseon vascular wall regeneration, initially
write to the editors at chembiol@-developed in collaboration with Ab-
cell.com.bott and based on the work at Li’s and
Keating’s labs. “I am studying vessel Alice A. McCarthy is a freelance sciencewriter
wall regeneration and the means to based in Gloucester, MA (alice@alicemccarthy.
com).help it regenerate correctly,” explains
Dr. Li. “In coronary restenosis, it is a
case of uncontrolled regeneration,”
he explains of his research in identi-
fying the natural biological factors
controlling excess regeneration. Hy-
dra’s efforts on this front include a
project designed to prevent post-
injury restenosis with drug-eluting
stents, such as those championed in
the last year through the Cordis Cy-
pher sirolimus-eluting stent (available
since April 2003) and Boston Scientif-
ic’s Taxus paclitaxel-eluting stent, just
FDA approved in March 2004. The
success of these products is not to
be underestimated. Following its first
full quarter of availability, Cypher
stents generated US sales of $429
million. The company is currently
seeking partners for continued devel-
opment of this project.
Hydra is focusing on the cardiovas-
cular market now. “We can imagine
having each patient who has suffered
from a heart attack, of which there
are over 800,000 each year in the US
alone, treated with our drugs to help
stimulate a normal repair process
following cardiac injury,” says Dr.
Larsen. Adds Mr. Gantz, “And if
we’re successful in the cardiac regen-
eration program, the implications for
future applications are obvious.” Other
potential areas may include retinal
cell regeneration to treat macular
degeneration, other diseased mus-
cle cells, and pancreatic cell regen-
eration.
Hydra is also developing high-
throughput screenings against se-
